November 7, 2023: Blood irradiator devices have been used for decades on cancer patients to try to prevent metastasis. NCHR agrees with FDA there is no evidence that they benefit patients and it is clear the radiation can be harmful. At an FDA Advisory Committee meeting in November 2023, we urged FDA to finally require scientific studies if companies want to continue to sell these devices.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter to NJ officials in Montclair and Essex County Regarding Harms from Artificial Turf
October 30, 2023: NCHR president Dr. Diana Zuckerman wrote a letter to NJ officials in Montclair and Essex County explaining why lead, PFAS, and other chemicals in artificial turf and rubber playground surfaces harm children’s health and safety.
Read More »NCHR’s Comments on Proposed Supplemental Guidance for CPSC Chronic Hazard Guidelines
NCHR criticizes CPSC’s revised proposal for chronic hazard guidelines for focusing on linear modeling that is not appropriate for endocrine disrupting chemical and for including a loophole that enables companies to do whatever they think is scientifically appropriate. We urge the CPSC to produce more explicit, rigorous guidelines based on sound science, since that is essential for the safety of consumers.
Read More »Letter to Officials in Kingston, NY Regarding Lead, PFAS, and Other Chemicals in Artificial Turf and PIP Rubber Playground Surfaces Causing Harm to Children’s Health and Safety
October 18, 2023: NCHR president Dr. Diana Zuckerman wrote a letter to officials in Kingston, NY explaining why lead, PFAS, and other chemicals in artificial turf and PIP rubber playground surfaces harm children’s health and safety.
Read More »NCHR Comments on FDA’s Draft Guidance on QTc Information in Human Prescription Drug and Biological Product Labeling
October 10, 2023, in response to FDA’s draft guidance on QTc product labeling to
correctly measure heartbeat contraction and relaxation, NCHR recommends that FDA specify a preferred method of calculating the QTc, provide methods for to improve
study design, and require studies of the impact of drug-drug and
drug-disease interactions. These changes to the guidance are needed to encourage industry to do the research needed to ensure the safety and effectiveness of their products.